Activation of deoxycytidine kinase during inhibition of DNA synthesis by 2-chloro-2'-deoxyadenosine (cladribine) in human lymphocytes

Biochemical Pharmacology

Volumn 56, Issue 9, 1998, Pages 1175-1179

  Sasvári Székely, Mária ^a   Spasokoukotskaja, Tatjana ^a   Szóke, Melinda ^a   Csapó, Zsolt ^a   Turi, Ágnes ^a   Szántó, Ildikó ^a   Eriksson, Staffan ^b   Staub, Mária ^a  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^b SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

Author keywords

2 chloro 2' deoxyadenosine; Cladribine; Deoxycytidine kinase; Human; Lymphocyte; Thymidine kinase

Indexed keywords

ANTILEUKEMIC AGENT; CLADRIBINE; CYCLOHEXIMIDE; DEOXYCYTIDINE KINASE; MESSENGER RNA; THYMIDINE KINASE;

ARTICLE; CONTROLLED STUDY; DNA SYNTHESIS; DNA SYNTHESIS INHIBITION; DRUG METABOLISM; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN PROCESSING;

EID: 0344973660     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(98)00108-7     Document Type: Article

References (30)

1. Amer ES and Eriksson S, Mammalian deoxyribonucleoside kinases. Pharmacol Ther 67: 155-186, 1995.
2. Plunkett W and Saunders PP, Metabolism and action of purine nucleoside analogues. Pharmacol Ther 49: 239-268, 1991.
3. Kawasaki H, Carrera PJ, Piro LD, Saren A, Kipps TJ and Carson DJ, Relationship of deoxycytidine kinase and cytoplasmic 5′-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. Blood 81: 597-601, 1993.
4. Arnér ES, Spasokoukotskaja T, Juliusson G and Eriksson S, Phosphorylation of 2-chlorodeoxyadenosine (CdA) in extracts of peripheral blood mononuclear cells of leukaemic patients. British J Haematology 87: 715-718, 1994.
5. Eriksson S, Arner E, Spasokoukotskaja T, Wang L, Karlsson A, Brosjö O, Gunven P, Julusson G and Liliemark J, Prospective and levels of deoxynucleoside kinases in normal and tumor cells: Implications for chemotherapy. Adv Enzyme Regul 34: 13-45, 1994.
6. Ruiz van Haperen VWT, Veerman G, Eriksson S, Boven E, Stegmann AP, Hermsen M, Vermorken JB, Pinedo HM and Peters GJ, Development and molecular characterization of a 2′,2′-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780. Cancer Res 54: 4138-43, 1994.
7. Datta NS, Shewach DS, Mitshell BS, Fox IH, Kinetic properties and inhibition of human T lymphoblast deoxycytidine kinase. J Biol Chem 264: 9359-9364, 1989.
8. Eriksson S, Kierdaszuk B, Munch-Petersen B, Öberg B and Johansson NG, Comparision of substrate specificities of human thymidine kinase 1 and 2 and deoxycytidine kinase toward antiviral and cytostatic nucleoside analogues. Biochem Biophys Res Commun 176: 586-592, 1991.
9. Beutler E, Cladribine (2-chlorodeoxyadenosine). Lancet 340: 952, 1992.
10. Juliusson G, Elmhorn-Rosenborg A and Liliemark J, Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N Engl J Med 327: 1056-61, 1992.
11. Carson DA, Carrera CJ, Wasson DB and Yamanaka H, Programmed cell death and adenine deoxynucleotide metabolism in human lymphocytes. Adv Enzyme Regul 27: 395-404, 1988.
12. Lassota P, Kazimierczuk Z, and Darzynkiewicz Z, Apoptotic death of lymphocytes upon treatment with 2-chloro-2′-deoxyadenosine (2-CdA). Arch lmmunol Ther Exp Warsz 42: 17-23, 1994.
13. Robertson LE, Meyn RE, Story M, Hittelman N and Plunkett W, Induction of apoptotic cell death in chronic lymphoid leukemia by 2-chloro-2′-deoxyadenosine and 9-β-D-arabinosyl-2-fluoroadenine. Blood 81: 143-150, 1993.
14. McConkey DJ, Zhivotovsky B and Orrhenius S, Apoptosis-molecular mechanisms and biomedical implications. Mol Aspects Med 17: 1-110, 1996.
15. Gandhi V, Estey E, Keating MJ, Chucrallah A and Plunkett W, Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: Pharmacokinetic, pharmacodynamic, and molecular interactions. Blood 87: 256, 1996.
16. Staub M, Spasokoukotskaja T, Sasvári-Székely M and Keszler G, The purine analogue cladribine (2-Cld Ado) is metabolized by deoxycytidine kinase (abstract). Drug Devel Res 37(SuppL): 178, 1996.
17. Ooi K, Ohkube T, Higashigawa M, Kawasaki H and Sakurai M, Increased deoxycytidine kinase activity by etoposide in L1210 Murine leucemic cells. Biol Pharm Bull 19: 1382, 1996.
18. Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB and Plunkett W, Inhibition of ribonucleotide reductase in CCRF-CEM cells by 2′2′-difluorodeoxycytidine. Molec Pharmacol 38: 567-572, 1990.
19. Sasvári-Székely M, Piróth Zs, Kazimierczuk Z and Staub M, A novel effect of the new antileukemic drug, 2-chloro-2′-deoxyadenosine, in human lymphocytes. Biochem Biophys Res Commun 203: 1378-84, 1994.
20. Fabianowska-Majewska K, Tybor K, Duley J and Simmonds A, The influence of 2-chloro-2′-deoxyadenosine on metabolism of deoxyadenosine in human primary CNS lymphoma. Biochem Pharmacol 50: 1379-83, 1995.
21. Spasokoukotskaja T, Sasvári-Székely M, Taljanidisz J and Staub M, Compartmentation of dCTP pools disappears after hydroxyurea or araC treatment in lympocytes. FEBS Letters 297: 151-154, 1992.
22. Xu YZ, Huang P and Plunkett W, Functional compartmentation of dCTP pools. Preferential utilization of salvaged deoxycytidine for DNA repair in human lymphoblasts. J Biol Chem 270: 631-637, 1995.
23. Puskas M, Staub M and Antoni F, In vitro synthesis and identification of lysosyme in human tonsillar cells. Biochem Med 13: 359, 1975.
24. Kazimierczuk Z, Cattam HB, Revanker RG and Robins RK, Synthesis of 2′-deoxytubercidine, 2′-deoxyadenosine and related 2′-deoxynucleosides via a novel directy stereospecific sodium salt glycosylation method. J Am Chem Soc 106: 6379-82, 1989.
25. Chirgwin JM, Przybyla AE, MacDonald RJ and Rutter WJ, Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 18: 5294-5299, 1979.
26. Chottiner EG, Shewach DS, Datta NS, Ashcraft E, Gribbin D, Ginsburg D, Fox IH and Mitchell BS, Cloning and expression of human deoxycytidine kinase cDNA. Proc Natl Acad Sci USA 88: 1531-1535, 1991.
27. Spasokoukotskaja T, Arnér ESJ, Brosjö O, Gunvén P, Juliusson G, Liliemark J and Eriksson S, Expression of deoxycytidine kinase and phosphorylation of 2-chlorodeoxyadenosine in human normal and tumour cells and tissues. Eur J Cancer 31A: 202-208, 1995.
28. Habteyesus A, Nordenskjöld A, Bohman C and Eriksson S, Deoxynucleoside phosphorylating enzymes in monkey and human tissues show great similarities, while mouse deoxycytidine kinase has a different substrate specifity. Biochem Pharmacol 42: 1829-36, 1991.
29. Lee LS and Cheng YC, Human deoxycytidine kinase II. Substrate specifity and kinetic behavior of the cytoplasmic and mitochondrial isoenzymes derived from blast cells of acute myelocytic leukemia. Biochemistry 15: 3686-3690, 1976.
30. Szyfter K, Sasvári-Székely M, Spasokukotskaja T, Antoni F and Staub M, Purification and properties of deoxycytidine kinase. Acta Biochim Biophys Acad Sci Hung 20: 173-182, 1985.